EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL)

Axel Nelson, Ellen Krabbe, Karl Björkström, Anne Huibers, Braslav Jovanovic, Christian U Blank, Gustav J Ullenhag, Hildur Helgadottir, Lars Ny, Roger Olofsson Bagge

European Journal of Cancer · 2025-06 · 224 · 115485

DOI: 10.1016/j.ejca.2025.115485 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025-06. Verfasst von Axel Nelson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, S…. Hauptthemen laut MEDLINE: Melanoma, Neoadjuvant Therapy, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Svenska Sällskapet för Medicinsk Forskning, Swedish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeoadjuvant TherapySkin NeoplasmsImmune Checkpoint InhibitorsImmunotherapyHumansMaleFemaleRetrospective StudiesMiddle AgedAgedSwedenNeoplasm StagingAdultAged, 80 and overCutaneous Malignant MelanomaNivolumab

Stichwörter der Autor:innen

Immune checkpoint inhibitorLymph node dissectionMelanomaNeoadjuvantPD-1Surgery

Substanzen

Immune Checkpoint InhibitorsNivolumab

Autor:innen und Institutionen

  • Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothen…
  • Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
  • Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; Wallenberg Centre for…

Förderung

  • Swedish Research Council
  • Svenska Sällskapet för Medicinsk Forskning
  • Swedish Cancer Society

Zitieren

APA

Nelson, A., Krabbe, E., Björkström, K., Huibers, A., Jovanovic, B., Blank, C. U., Ullenhag, G. J., Helgadottir, H., Ny, L., & Olofsson Bagge, R. (2025). Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL). European Journal of Cancer, 224, 115485. https://doi.org/10.1016/j.ejca.2025.115485

Vancouver

Nelson A, Krabbe E, Björkström K, Huibers A, Jovanovic B, Blank CU, et al. Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL). European Journal of Cancer. 2025;224:115485. doi:10.1016/j.ejca.2025.115485

BibTeX
@article{Nelson2025,
  author = {Nelson, Axel and Krabbe, Ellen and Björkström, Karl and Huibers, Anne and Jovanovic, Braslav and Blank, Christian U and Ullenhag, Gustav J and Helgadottir, Hildur and Ny, Lars and Olofsson Bagge, Roger},
  title = {Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL)},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {224},
  pages = {115485},
  doi = {10.1016/j.ejca.2025.115485}
}
Kostenlos starten →